Moderna Makes its Mark

Early results from human testing of a vaccine against the novel coronavirus suggest—but don’t prove—that it offers some immunity, The Washington Post reports.
 
Moderna reported yesterday that 8 patients given low and medium doses of their vaccine developed virus-fighting antibodies comparable to those of recovered COVID-19 patients.

The findings are an early step in proving the drug’s safety and efficacy. Nevertheless, they sent Moderna’s stock soaring—days after one of the biotech's directors, Moncef Slaoui, resigned to join the Trump administration’s “Warp Speed” vaccine initiative.

Amid concerns about conflicts of interest, Slaoui announced that he will divest from Moderna Inc, according to the Los Angeles Times.

The Moderna vaccine is 1 of 8 vaccines being tested in humans worldwide.